Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2023-08-31 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
关于募集资金使用完毕并注销募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the use of raised funds and the closure of the special accounts for those funds. It details the fundraising amount, usage, and the formal closure of the accounts, including related agreements termination. It does not contain financial statements or detailed financial performance data. The document is short (1448 characters) and serves as a formal notification about the fundraising usage completion and account closure. This fits the category of Capital/Financing Update (CAP), as it relates to fundraising activities and capital management updates.
2023-08-31 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Huizhou Jin Hao Medical Technology Co., Ltd. regarding the progress of its share repurchase program. It details the repurchase plan, including the purpose, method, price, quantity, funding source, implementation period, and adjustments to the repurchase price. It also provides specific data on the number of shares repurchased to date and the amount spent. The document is titled as a "回购进展情况公告" which translates to "Repurchase Progress Announcement." This type of document is a report on the company's transactions in its own shares (share buybacks). It is not a financial report, earnings release, or regulatory filing, but specifically a report on share repurchase activity. Therefore, the appropriate classification is "Transaction in Own Shares (POS)." The document length is 1779 characters, which is consistent with an announcement rather than a full report. Confidence is high due to clear keywords such as "回购" (repurchase), "股份回购方案" (share repurchase plan), and detailed repurchase progress data.
2023-08-31 Chinese
第二届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Huizhou Jin Hao Medical Technology Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2023 semi-annual report and related disclosures. The document references the actual semi-annual report and other reports being disclosed separately on the Beijing Stock Exchange information platform, indicating this document itself is not the report but a meeting resolution announcement. The document is short (1510 characters) and primarily serves to announce the resolutions passed by the Supervisory Board, not to present financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim Report (IR) or Annual Report (10-K).
2023-08-28 Chinese
第二届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting, including voting results and descriptions of agenda items. It references multiple other documents disclosed on the stock exchange information platform but does not itself contain financial statements or detailed financial data. The content focuses on board meeting procedures, resolutions, and approvals, which aligns with announcements about board or management decisions. The document length is under 5,000 characters and is primarily a meeting resolution announcement rather than a full report or financial statement. Therefore, it fits best under the category of Board/Management Information (MANG).
2023-08-28 Chinese
北京大成（广州）律师事务所关于2022年股权激励计划注销部分股票期权、调整首次授予及预留授予股票期权数量和行权价格的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation and adjustment of stock options and restricted stock under a 2022 stock incentive plan of a company. It discusses legal compliance with company law, securities law, and stock exchange regulations, and provides detailed legal analysis and conclusions on the stock option adjustments and cancellations. The document is not a financial report, earnings release, or management discussion, but a standalone legal opinion related to stock incentive plans. This fits the category of Audit Report / Information (AR), which includes applied accounting principles and regulatory compliance reports excluding full annual reports. The document is substantive and over 6000 characters, so it is not a mere announcement or certification. Therefore, the best classification is AR with high confidence.
2023-08-28 Chinese
独立董事关于第二届董事会第二十七次会议有关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a specific board meeting, including stock option cancellations and adjustments to a stock incentive plan. It references compliance with company bylaws and legal regulations, and it is dated shortly after the board meeting. The content focuses on governance and approval of stock incentive plan changes rather than financial results or audit findings. The document length is short (826 characters), and it is not a full report but an opinion statement related to board decisions. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2023-08-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.